Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TmCD19-IL18 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| NHL Dose Level 1 | EXPERIMENTAL | 7x10\^6 TmCD19-IL18 cells administered as a single intravenous (IV) infusion |
| NHL Dose Level -1 | EXPERIMENTAL | 2x10\^6 TmCD19-IL18 cells administered as a single intravenous (IV) infusion |
| NHL Dose Level 2 | EXPERIMENTAL | 2x10\^7 TmCD19-IL18 cells administered as a single intravenous (IV) infusion |
| NHL Dose Level 3 | EXPERIMENTAL | 6x10\^7 TmCD19-IL18 cells administered as a single intravenous (IV) infusion |
| NHL Dose Level 1a | EXPERIMENTAL | 5x10\^6 TmCD19-IL18 CAR T cells |
| Name | Type | Description |
|---|---|---|
| TmCD19-IL18 | BIOLOGICAL | autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
1. Signed informed consent form 2. Documentation of CD19 expression on malignant cells by flow cytometry/IHC from a CLIA certified laboratory. a. Cohort A (NHL): Within 6 months of physician-investigator confirmation of eligibility as long as there has been no intervening CD19 directed therapy s...
TmCD19-IL18 is an investigational monoclonal antibody being developed for the treatment of Non Hodgkin Lymphoma. It is currently in Phase 1 clinical development and is being studied in patients with CD19-positive cancers. The drug is not yet approved and remains under investigation.
TmCD19-IL18 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with Non Hodgkin Lymphoma.
TmCD19-IL18 is in Phase 1 clinical development. It is an investigational drug being studied for the treatment of Non Hodgkin Lymphoma. The drug has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy.
TmCD19-IL18 is being evaluated in a Phase 1 clinical trial with the identifier NCT05989204, titled 'TmCD19-IL18 in CD19+ Cancers'. This trial is active but not recruiting, with an enrollment of 26 participants, and is being conducted in the United States for patients with Non Hodgkin Lymphoma.
Yes, TmCD19-IL18 is a monoclonal antibody. It is being developed as a therapeutic for Non Hodgkin Lymphoma and is currently in Phase 1 clinical trials. The drug is designed to target CD19-positive cancers, as indicated by the ongoing clinical trial in this patient population.